JP2004508043A - Ｔｎｆレセプター様分子およびその使用 - Google Patents

Ｔｎｆレセプター様分子およびその使用 Download PDF

Info

Publication number
JP2004508043A
JP2004508043A JP2002525769A JP2002525769A JP2004508043A JP 2004508043 A JP2004508043 A JP 2004508043A JP 2002525769 A JP2002525769 A JP 2002525769A JP 2002525769 A JP2002525769 A JP 2002525769A JP 2004508043 A JP2004508043 A JP 2004508043A
Authority
JP
Japan
Prior art keywords
seq
polypeptide
amino acid
activity
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2002525769A
Other languages
English (en)
Japanese (ja)
Other versions
JP2004508043A5 (enExample
Inventor
セイル，　ラース　アイド
イェー，　リチャード
シルビガー，　スコット　マイケル
ユー，　ガン
セナルディ，　ジョージオ
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of JP2004508043A publication Critical patent/JP2004508043A/ja
Publication of JP2004508043A5 publication Critical patent/JP2004508043A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7151—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for tumor necrosis factor [TNF], for lymphotoxin [LT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Communicable Diseases (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Pain & Pain Management (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
  • Hydrogenated Pyridines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2002525769A 2000-09-05 2001-09-05 Ｔｎｆレセプター様分子およびその使用 Pending JP2004508043A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US23019100P 2000-09-05 2000-09-05
PCT/US2001/027631 WO2002020762A2 (en) 2000-09-05 2001-09-05 Tnf receptor-like molecules and uses thereof

Publications (2)

Publication Number Publication Date
JP2004508043A true JP2004508043A (ja) 2004-03-18
JP2004508043A5 JP2004508043A5 (enExample) 2008-09-11

Family

ID=22864263

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2002525769A Pending JP2004508043A (ja) 2000-09-05 2001-09-05 Ｔｎｆレセプター様分子およびその使用

Country Status (10)

Country Link
US (3) US7153669B2 (enExample)
EP (1) EP1317536B1 (enExample)
JP (1) JP2004508043A (enExample)
AT (1) ATE431405T1 (enExample)
AU (2) AU8881201A (enExample)
CA (1) CA2421588C (enExample)
DE (1) DE60138715D1 (enExample)
ES (1) ES2327102T3 (enExample)
MX (1) MXPA03001930A (enExample)
WO (1) WO2002020762A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531428A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003020932A1 (en) * 2001-09-03 2003-03-13 Takeda Chemical Industries, Ltd. Novel secretory proteins and dna thereof
EP1338609A1 (de) * 2002-02-21 2003-08-27 MEMOREC Stoffel GmbH-Medizinisch-Molekulare Entwicklung, Köln Ein weiterer KDR Rezeptor und seine Anwendung
US8202701B2 (en) * 2004-10-08 2012-06-19 Georgia Tech Research Corporation Microencapsulation of cells in hydrogels using electrostatic potentials
JP5808323B2 (ja) 2009-06-22 2015-11-10 アムジエン・インコーポレーテツド 化学的に制御されたレドックス状態を用いたタンパク質のリフォールディング
RU2012127383A (ru) 2009-12-02 2014-01-10 Акселерон Фарма Инк. Композиции и способы для увеличения времени полужизни fc-слитых белков в сыворотке
WO2012075238A1 (en) 2010-12-02 2012-06-07 Genentech, Inc. Novel receptor-ligand interaction and uses thereof
EP2718328A4 (en) 2011-06-08 2014-12-24 Acceleron Pharma Inc COMPOSITIONS AND METHODS FOR INCREASING THE HALF TIME OF SERUM
UY35148A (es) 2012-11-21 2014-05-30 Amgen Inc Immunoglobulinas heterodiméricas
WO2014144817A2 (en) 2013-03-15 2014-09-18 Amgen Inc. Inhibitory polypeptides specific to wnt inhibitors
WO2015035215A1 (en) 2013-09-05 2015-03-12 Amgen Inc. Fc-containing molecules exhibiting predictable, consistent, and reproducible glycoform profiles
EP3143404B1 (en) 2014-05-16 2018-08-29 Amgen Inc. Assay for detecting th1 and th2 cell populations
CN110418846A (zh) 2017-03-14 2019-11-05 美国安进公司 细胞培养物中产生的抗体的总去岩藻糖基化糖型的控制
SG11202009216YA (en) 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
KR20220069982A (ko) 2019-09-26 2022-05-27 암젠 인크 항체 조성물의 생산 방법
US11926672B2 (en) * 2019-12-20 2024-03-12 Amgen Inc. Mesothelin-targeted CD40 agonistic multispecific antibody constructs for the treatment of solid tumors
WO2021247892A1 (en) 2020-06-04 2021-12-09 Amgen Inc. Assessment of cleaning procedures of a biotherapeutic manufacturing process
AU2021360897A1 (en) 2020-10-15 2023-05-25 Amgen Inc. Relative unpaired glycans in antibody production methods
TW202317614A (zh) 2021-06-07 2023-05-01 美商安進公司 使用岩藻糖苷酶控制糖基化蛋白的去岩藻糖基化水平
JP2024537100A (ja) 2021-10-05 2024-10-10 アムジエン・インコーポレーテツド Ｆｃガンマ受容体ＩＩ結合、及びグリカン含量
WO2023215725A1 (en) 2022-05-02 2023-11-09 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy
WO2024220916A1 (en) 2023-04-20 2024-10-24 Amgen Inc. Methods of determining relative unpaired glycan content
CN116459344B (zh) * 2023-04-28 2025-03-18 上海市生物医药技术研究院 一种MNSFβ/RC3H1 PPI干扰多肽的抗炎治疗应用
WO2025038600A1 (en) 2023-08-14 2025-02-20 Amgen Inc. Methods for reducing yellow color
WO2025101820A1 (en) 2023-11-08 2025-05-15 Fred Hutchinson Cancer Center Compositions and methods for cellular immunotherapy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK0393438T3 (da) 1989-04-21 2005-05-30 Amgen Inc TNF-receptor, TNF-bindende proteiner og DNAér, der koder herfor
IL95031A (en) 1989-07-18 2007-03-08 Amgen Inc Method for the production of a human recombinant tumor necrosis factor inhibitor
US5194596A (en) * 1989-07-27 1993-03-16 California Biotechnology Inc. Production of vascular endothelial cell growth factor
US5350836A (en) * 1989-10-12 1994-09-27 Ohio University Growth hormone antagonists
DE4004317A1 (de) 1990-02-13 1991-08-14 Basf Ag Neue 3-substituierte pyridinmethanole und diese enthaltende fungizide
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein
US5843789A (en) * 1995-05-16 1998-12-01 Neomecs Incorporated Method of analysis of genomic biopolymer and porous materials for genomic analyses
JP2002506875A (ja) * 1998-03-16 2002-03-05 ミレニアム ファーマシューティカルズ インク． 第１８ｐ染色体関連障害の診断及び治療のための方法及び組成物
US6660843B1 (en) * 1998-10-23 2003-12-09 Amgen Inc. Modified peptides as therapeutic agents
WO2001055343A1 (en) 2000-01-31 2001-08-02 Human Genome Sciences, Inc. Nucleic acids, proteins, and antibodies
US6783969B1 (en) * 2001-03-05 2004-08-31 Nuvelo, Inc. Cathepsin V-like polypeptides

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
JPN6011004054, ""ｗｊ４５ｅ０７．ｘ１ ＮＣＩ＿ＣＧＡＰ＿Ｌｕ１９ Ｈｏｍｏ ｓａｐｉｅｎｓ ｃＤＮＡ ｃｌｏｎｅ ＩＭＡＧＥ：２４０５７９６ ３−， ｍＲＮＡ ｓｅｑｕｅｎｃｅ"", ＮＣＢＩ ＥＳＴ *
JPN6011004056, ""ｗｆ２４ｄ０１．ｘ１ Ｓｏａｒｅｓ＿ＮＦＬ＿Ｔ＿ＧＢＣ＿Ｓ１ Ｈｏｍｏ ｓａｐｉｅｎｓ ｃＤＮＡ ｃｌｏｎｅ ＩＭＡＧＥ：２３５６５１３ ３− ｓｉｍｉｌａｒ ｔｏ ｃｏｎｔａｉｎｓ ＭＥＲ２２．ｔ", ＮＣＢＩ ＥＳＴ *
JPN6011004058, ""６０１１０９１５８Ｆ１ ＮＩＨ＿ＭＧＣ＿１６ Ｈｏｍｏ ｓａｐｉｅｎｓ ｃＤＮＡ ｃｌｏｎｅ ＩＭＡＧＥ：３３４９９５８ ５−， ｍＲＮＡ ｓｅｑｕｅｎｃｅ"", ＮＣＢＩ ＥＳＴ *
JPN6011004059, ""ｔｎ４５ｇ１０．ｘ１ ＮＣＩ＿ＣＧＡＰ＿Ｂｒｎ２５ Ｈｏｍｏ ｓａｐｉｅｎｓ ｃＤＮＡ ｃｌｏｎｅ ＩＭＡＧＥ：２１７０６２６ ３−， ｍＲＮＡ ｓｅｑｕｅｎｃｅ"", ＮＣＢＩ ＥＳＴ *
JPN6011004060, ""ｑａ７１ｂ０３．ｘ１ Ｓｏａｒｅｓ＿ｆｅｔａｌ＿ｈｅａｒｔ＿ＮｂＨＨ１９Ｗ Ｈｏｍｏ ｓａｐｉｅｎｓ ｃＤＮＡ ｃｌｏｎｅ ＩＭＡＧＥ：１６９２１７３ ３− ｓｉｍｉｌａｒ ｔｏ ｃｏｎｔａｉｎｓ", ＮＣＢＩ ＥＳＴ *
JPN6011004062, ""ｘｖ３０ｄ０６．ｘ１ Ｓｏａｒｅｓ＿ＮＦＬ＿Ｔ＿ＧＢＣ＿Ｓ１ Ｈｏｍｏ ｓａｐｉｅｎｓ ｃＤＮＡ ｃｌｏｎｅ ＩＭＡＧＥ：２８１４６３５ ３−， ｍＲＮＡ ｓｅｑｕｅｎｃｅ"", ＮＣＢＩ ＥＳＴ *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2012531428A (ja) * 2009-06-25 2012-12-10 アムジエン・インコーポレーテツド 哺乳類以外の系で発現されるタンパク質の捕獲精製プロセス

Also Published As

Publication number Publication date
EP1317536A2 (en) 2003-06-11
CA2421588A1 (en) 2002-03-14
WO2002020762A3 (en) 2002-08-08
WO2002020762A8 (en) 2004-03-04
MXPA03001930A (es) 2003-06-19
WO2002020762A2 (en) 2002-03-14
AU2001288812B2 (en) 2007-05-10
ES2327102T3 (es) 2009-10-26
AU8881201A (en) 2002-03-22
US20070015219A1 (en) 2007-01-18
EP1317536B1 (en) 2009-05-13
US7569387B2 (en) 2009-08-04
US20020150977A1 (en) 2002-10-17
CA2421588C (en) 2010-01-26
DE60138715D1 (de) 2009-06-25
US20090325880A1 (en) 2009-12-31
US7153669B2 (en) 2006-12-26
ATE431405T1 (de) 2009-05-15

Similar Documents

Publication Publication Date Title
US20090325880A1 (en) Tnf receptor-like molecules and uses thereof
US20060024267A1 (en) TNFr/OPG-like molecules and uses thereof
AU2001288812A1 (en) TNF receptor-like molecules and uses thereof
JP2004500063A5 (enExample)
JP2004504064A (ja) Ｉｌ−１７分子およびその用途
AU2001259029B2 (en) Il-17 receptor like molecules and uses thereof
US20020045213A1 (en) IL-17 receptor like molecules and uses thereof
JP2007014331A (ja) インターフェロン様分子およびその使用
AU784727B2 (en) IL-17 like molecules and uses thereof
MXPA04005956A (es) Moleculas tipo il-17 y usos de las mismas.
AU1805101A (en) Interleukin-1 receptor antagonist-like molecules and uses thereof
JP3842647B2 (ja) インターロイキン−１レセプターアンタゴニスト関連分子およびその使用
HUP0203689A2 (hu) Interleukin-1 receptor antagonistaszerű molekulák és ezek használata
JP2003516132A (ja) インターロイキン−１レセプターアンタゴニスト様分子およびその使用
US20030099980A1 (en) IL-17 receptor like molecules and uses thereof
AU2007200885A1 (en) IL-17 Receptor Like Molecules and Uses Thereof

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080723

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20080723

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20110126

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20110909